#AANAM – Ublituximab Reduced Relapse Rate, Disability Progression in Twin Trials

#AANAM – Ublituximab Reduced Relapse Rate, Disability Progression in Twin Trials

292542

#AANAM – Ublituximab Reduced Relapse Rate, Disability Progression in Twin Trials

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’ annualized relapse rates and lowering the number of brain lesions over nearly two years, according to data from the ULTIMATE clinical trials. Those findings were presented by Lawrence Steinman, MD,…

You must be logged in to read/download the full post.